Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A

被引:99
|
作者
Carmignac, Virginie [1 ]
Svensson, Martina
Korner, Zandra
Elowsson, Linda
Matsumura, Cintia
Gawlik, Kinga I.
Allamand, Valerie [2 ,3 ,4 ,5 ]
Durbeej, Madeleine
机构
[1] Lund Univ, Dept Expt Med Sci, Muscle Biol Unit, BMC B12, S-22184 Lund, Sweden
[2] Univ Paris 06, UPMC, IFR14, Paris, France
[3] CNRS, UMR7215, Paris, France
[4] INSERM, U974, Paris, France
[5] Inst Myol, Paris, France
基金
瑞典研究理事会;
关键词
CONGENITAL MUSCULAR-DYSTROPHY; EXPRESSION; PATHOGENESIS; DEGRADATION; DISEASE; FOXO3; DYSTROGLYCAN; APOPTOSIS; SURVIVAL; PATHWAY;
D O I
10.1093/hmg/ddr427
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Congenital muscular dystrophy caused by laminin alpha 2 chain deficiency (also known as MDC1A) is a severe and incapacitating disease, characterized by massive muscle wasting. The ubiquitin-proteasome system plays a major role in muscle wasting and we recently demonstrated that increased proteasomal activity is a feature of MDC1A. The autophagy-lysosome pathway is the other major system involved in degradation of proteins and organelles within the muscle cell. However, it remains to be determined if the autophagy-lysosome pathway is dysregulated in muscular dystrophies, including MDC1A. Using the dy(3K)/dy(3K) mouse model of laminin alpha 2 chain deficiency and MDC1A patient muscle, we show here that expression of autophagy-related genes is upregulated in laminin alpha 2 chain-deficient muscle. Moreover, we found that autophagy inhibition significantly improves the dystrophic dy(3K)/dy(3K) phenotype. In particular, we show that systemic injection of 3-methyladenine (3-MA) reduces muscle fibrosis, atrophy, apoptosis and increases muscle regeneration and muscle mass. Importantly, lifespan and locomotive behavior were also greatly improved. These findings indicate that enhanced autophagic activity is pathogenic and that autophagy inhibition holds a promising therapeutic potential in the treatment of MDC1A.
引用
收藏
页码:4891 / 4902
页数:12
相关论文
共 26 条
  • [21] Early skeletal muscle pathology and disease progress in the dy3K/ dy3K mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency
    Gawlik, Kinga, I
    Korner, Zandra
    Oliveira, Bruno M.
    Durbeej, Madeleine
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [22] E2F transcription factor-1 deficiency reduces pathophysiology in the mouse model of Duchenne muscular dystrophy through increased muscle oxidative metabolism
    Blanchet, Emilie
    Annicotte, Jean-Sebastien
    Pradelli, Ludivine A.
    Hugon, Gerald
    Matecki, Stefan
    Mornet, Dominique
    Rivier, Francois
    Fajas, Lluis
    HUMAN MOLECULAR GENETICS, 2012, 21 (17) : 3910 - 3917
  • [23] Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation
    Antoine Muchir
    Young Jin Kim
    Sarah A Reilly
    Wei Wu
    Jason C Choi
    Howard J Worman
    Skeletal Muscle, 3
  • [24] Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation
    Muchir, Antoine
    Kim, Young Jin
    Reilly, Sarah A.
    Wu, Wei
    Choi, Jason C.
    Worman, Howard J.
    SKELETAL MUSCLE, 2013, 3
  • [25] Gene therapy of PKU in a mouse model by ectopic expression of PAH and its BH4-cofactor genes in skeletal muscle by a triple-cistronic AAV2-based pseudotype 1 vector
    Thony, B.
    Harding, C. O.
    Rebuffat, A.
    Elzaouk, L.
    Wolff, J.
    Ding, Z.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 71 - 71
  • [26] Therapeutic Correction of PKU in a Mouse Model by Ectopic Expression of PAH and Its BH4-Cofactor Genes in Skeletal Muscle by a Recombinant Triple-Cistronic AAV2-Based Pseudotype 1 Vector
    Ding, Zhaobing
    Harding, Cary O.
    Rebuffat, Alexandre
    Elzaouk, Lina
    Wolff, Jon A.
    Thony, Beat
    MOLECULAR THERAPY, 2006, 13 : S155 - S155